1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd.

NPKYF
Nippon Kayaku Co., Ltd.US flagOther OTC
8.44
USD
- -
- -
1.25BMarket Cap
2012 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
811.52
883.22
893.22
905.42
918.19
969.58
997.08
1,014.69
1,015.17
1,093.9
1,183.07
1,216.73
1,362.48
626.91
Basic EPS, GAAP
62.89
92.25
86.38
96.08
90.22
89.45
85.77
74.25
73.62
101.7
89.36
24.8
107.17
-11.94
Free Cash Flow per Basic Share
56.84
65.31
25.12
26.49
95.52
41.45
61.98
62.74
63.73
80.94
42.06
43.53
-33.53
- -
Dividend per Share
19.93
19.96
27.44
25.11
30.15
32.42
29.93
30.02
29.92
30.01
45.03
47.36
45.27
- -
Book Value per Share
745.29
918.34
1,030.15
1,075.55
1,120.72
1,203.22
1,247.74
1,225.71
1,332.05
1,459.05
1,532.33
1,625.18
1,673.23
1,609.26
Tangible Book Value per Share
720.61
901.86
1,015.53
1,063.23
1,107
1,182.53
1,227.57
1,206.02
1,292.02
1,413.96
1,492.89
1,602.9
1,647.89
1,584.54
Basic Weighted Avg Shares
181
181
181
180
173
173
173
173
171
169
168
166
163
166
Sales/Revenue/Turnover
147,119
160,068
161,857
162,936
159,112
167,882
172,640
175,133
173,384
184,805
198,380
201,791
222,584
103,883
Operating Margin (%)
13.19
15.05
13.78
13.33
12.35
13.47
11.55
9.98
8.76
11.39
10.84
3.64
9.17
2.47
Depreciation Expense
9,931
10,435
10,743
11,238
11,343
11,673
11,969
12,584
13,473
14,099
14,240
14,402
14,077
- -
Net Income, GAAP
11,401
16,718
15,653
17,291
15,635
15,488
14,851
12,815
12,574
17,181
14,984
4,113
17,508
-1,979
Effective Tax Rate (%)
33.09
28.98
29.89
27.27
26.88
26.52
26.32
29.01
28.15
27.24
28.27
42
20.12
56.43
Profit Margin (%)
7.75
10.44
9.67
10.61
9.83
9.23
8.6
7.32
7.25
9.3
7.55
2.04
7.87
-1.91
Working Capital
82,491
100,572
102,367
111,430
112,281
115,068
120,546
114,302
119,361
130,083
146,988
143,331
151,188
132,519
LT Debt
6,934
13,717
9,518
12,460
8,201
7,577
8,778
18,182
15,770
9,474
16,200
18,000
34,884
15,400
Total Equity
144,017
177,933
199,678
200,490
205,863
220,616
229,042
210,018
228,272
246,424
255,024
270,547
268,518
264,200
Return on Invested Capital (%)
8.07
9.37
7.45
7.19
6.45
7.24
6.09
5.16
4.51
5.95
5.68
1.47
5.29
- -
Return on Capital (%)
6.77
8.72
7.07
7.55
6.81
6.54
5.92
5.41
5.26
6.73
5.58
1.43
5.75
1.43
Return on Common Equity (%)
8.67
11.09
8.87
9.21
8.16
7.7
7
6.03
5.76
7.26
6
1.57
6.52
-0.75

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,450
- -
13,300
LT Borrowings
18,000
- -
15,400
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
166
166
164
Market Capitalization
- -
- -
208,560

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
203,146
- -
195,196
Cash, Cash Equivalents & STI
66,177
- -
53,786
Accounts Receivable, Net
60,267
- -
59,840
Inventories
67,008
- -
71,886
Total Current Liabilities
59,815
- -
62,677
Payables & Accruals
- -
- -
- -
ST Debt
13,450
- -
13,300
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.12%
5.09%
-0.75%
Free Cash Flow
5%
-39.16%
-175.87%
Net Income, GAAP
25.72%
55.02%
325.67%
Sales/Revenue/Turnover
3.31%
4.99%
10.3%
Total Cash Common Dividend
5.12%
8.99%
-5.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,584
49,324
51,845
52,038
201,791
2025
- -
- -
- -
- -
222,584
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.05
- -
- -
- -
24.8
2025
- -
- -
- -
- -
107.17
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
47.36
2025
- -
- -
- -
- -
45.27
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Shigeyuki Kawamura
Full Time Employees
5,946
Sector
Basic Materials
Industry
Chemicals
Address
Meiji Yasuda Seimei Building Tokyo TY Japan 100-0005
IPO Date
Jun 28, 2018
Website
nipponkayaku.co.jp
Similar Companies
Foseco India Limited (FOSECOIND.NS)
PURE Bioscience, Inc. (PURE)
LyondellBasell Industries N.V. (0EDD.L)
Lords Chloro Alkali Limited (LORDSCHLO.NS)
Orbia Advance Corporation, S.A.B. de C.V. (MXCHY)
Ritesh International Ltd (RITESHIN.BO)
Business
Nippon Kayaku Co., Ltd. develops, manufactures and sells functional chemicals, pharmaceuticals, safety systems and agrochemicals in Japan and internationally. The company operates through Mobility and Imaging, Fine Chemicals and Life Sciences business segments; the Fine Chemicals segment supplies epoxy resins, maleimide resins, epoxy resin hardeners, reactive flame-retardant resins, acrylic esters, UV-curable resins for resists, liquid and dry film resists, LCD and semiconductor cleaners, sealants for liquid crystal displays, semiconductor manufacturing equipment including laminators, removers, mounters and UV irradiation machines, pigments for inkjet printers, dyes for inkjet textile printing, industrial inkjet inks, materials for image sensors, dichroic dyes for photochromic glass, near-infrared absorbers, dyes for textiles and paper, colorants for resins, thermal imaging colorants, pigment derivatives and catalysts for acrylic acid, acrolein and methacrylic acid production; the Mobility and Imaging segment provides airbag inflators, micro gas generators for seatbelt pretensioners, squibs, liquid crystal display parts, projector parts and x-ray analysis equipment parts; the Life Sciences segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates, photodynamic diagnostic agents, in vitro diagnostic medicines, intravascular embolization materials, food additives, health food ingredients, food quality preservatives, cleaning and disinfecting agents, agricultural insecticides, herbicides, fungicides, acaricides, epidemic prevention insecticides, soil fungicides and animal repellents. Nippon Kayaku also engages in real estate leasing services. Founded in 1916 and headquartered in Tokyo's Chiyoda-ku at the Meiji Yasuda Seimei Building, the company--formerly Nihon Kayaku Seizo Co., Ltd.--maintains global operations including subsidiaries like Taiwan Nippon Kayaku Co., Ltd. and overseas offices in locations such as New York, Dusseldorf and Shanghai. In August 2025, Nippon Kayaku executed a shareholders agreement with Formiica Pharmaceuticals Pte. Ltd. and CBC Co., Ltd. to establish a Singapore-based joint venture focused on in-licensing pharmaceutical products for Asia including Japan and Oceania, granting Nippon Kayaku preferential rights for Japanese development and sales to bolster its domestic pharmaceutical operations; the company also launched oncology medicine IBTROZIR Capsules 200mg in November 2025, adding to its anti-cancer portfolio.